Drug Discovery World Editor Reece Armstrong speaks to Dr Jan Davidson-Moncada, Chief Medical Officer at Imviva Biotech about the development of CAR-T cell therapies and the company’s activities in this space. RA: What are the biggest challenges when developing CAR-T cell therapies? JDM: CAR-T therapies face several formidable barriers. Autologous approaches made from a patient’s own T-cells are effective but costly (often exceeding […]
To read this content in full, you need to login.
Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!